Filing Analysis
ImmuCell Corporation announced its unaudited financial results for the fiscal quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings release via press release.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Quarter ended June 30, 2026
- The results announced are unaudited financial results.
- Information is provided via Exhibit 99.1 (Press Release).
ImmuCell Corporation announced a 11.5% year-over-year increase in product sales for Q2 2026 compared to Q2 2025, based on preliminary and unaudited results.
📋 Key Facts
- Reported a 11.5% increase in product sales for the quarter ended June 30, 2026, vs. Q2 2025.
- Sales data is based on preliminary, unaudited results.
- The announcement was made via press release on July 9, 2026.
ImmuCell Corporation reported the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. All proposed measures, including the election of directors and the ratification of the auditor, were approved.
📋 Key Facts
- The 2026 Annual Meeting was held via remote communication on June 11, 2026.
- 7,397,695 shares were represented, accounting for over 81% of total outstanding eligible votes.
- Seven director nominees were elected to one-year terms.
- The 2025 Stock Option and Incentive Plan was approved (90.39% of voting shares).
- Wipfli LLP was ratified as the Independent Registered Public Accounting Firm for the year ending December 31, 2026.
- An amendment to the Certificate of Incorporation regarding the exculpation of officers was approved.
ImmuCell Corporation announced a two-phase manufacturing capacity expansion program to pivot resources from its Re-Tain® product to its flagship First Defense® product line. The first phase involves renovating facilities and adding a new freeze dryer to meet growing demand.
📋 Key Facts
- Board of Directors authorized the expansion program on June 4, 2026.
- Phase 1 involves renovating the former Re-Tain® facility and adding a new freeze dryer.
- Phase 1 is estimated to cost approximately $3.5 million and take 12 months to complete.
- Phase 2 will focus on repurposing Re-Tain® equipment and adding automation to expand First Defense® colostrum processing capacity.
- The company previously suspended in-house manufacturing of Re-Tain® in late 2025/early 2026.
ImmuCell Corporation reported its unaudited financial results for the first quarter ended March 31, 2026. The announcement was made through a press release furnished as an exhibit to the filing.
📋 Key Facts
- Unaudited financial results for the quarter ended March 31, 2026
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- Press release dated April 14, 2026 included as Exhibit 99.1, despite the filing date of May 14, 2026
ImmuCell Corporation has entered into a Settlement Deed with Norbrook Laboratories Limited to resolve all claims related to a 2019 Development Services and Commercial Supply Agreement. Under the terms of the settlement, Norbrook will pay ImmuCell $2 million following the expiration of their previous agreement on March 31, 2026.
🚩 Red Flags
- Expiration of the underlying 2019 Development Services and Commercial Supply Agreement as of March 31, 2026, which may impact future revenue streams.
📋 Key Facts
- Settlement Deed signed on May 8, 2026, with Norbrook Laboratories Limited.
- Norbrook to pay ImmuCell a sum of $2,000,000.
- The settlement resolves claims related to a 2019 Development Services and Commercial Supply Agreement.
- The underlying agreement expired on March 31, 2026.
- The deed includes confidentiality undertakings and no admission of liability.
ImmuCell Corporation announced a significant board refresh involving the resignation of three directors and the appointment of two new members with deep industry expertise. The departures include former long-time CEO Michael Brigham and current VP of Sales Bobbi Jo Brockmann, effective April 15, 2026.
🚩 Red Flags
- Simultaneous departure of three board members, representing a significant loss of institutional knowledge.
- Departure of the former long-term CEO from the board less than a year after his retirement as CEO.
📋 Key Facts
- Three directors (Bryan K. Gathagan, Michael F. Brigham, and Bobbi Jo Brockmann) are resigning or retiring from the Board effective April 15, 2026.
- Michael F. Brigham served as President and CEO for over 25 years (2000-2025) and has been a director since 1999.
- Bobbi Jo Brockmann will remain the Company’s Vice President of Sales and Marketing despite resigning from the Board.
- New director Gilles Guillemette, DVM, brings 30+ years of experience from Elanco, Bayer, and Trupanion.
- New director Anthony DiMarco, Ph.D., brings 21 years of experience from IDEXX as VP of R&D and Global Manufacturing.
- A new Strategy & Technology Committee has been formed, which both new directors will join.
ImmuCell Corporation announced preliminary unaudited sales results for the first quarter of 2026, reporting a 28.4% increase in product sales compared to the first quarter of 2025. The disclosure was made via a press release on April 8, 2026, following the close of the quarter on March 31, 2026.
📋 Key Facts
- Preliminary unaudited product sales for Q1 2026 increased by 28.4% compared to Q1 2025.
- The reporting period ended March 31, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The report was signed by Timothy C. Fiori, Chief Financial Officer.
ImmuCell Corporation announced that director Steven A. Rosgen will retire from the Board effective April 1, 2026, following a previous notice of non-reelection. Kathy V. Turner, a former executive at IDEXX Laboratories and Abbott Laboratories, has been elected to fill the vacancy and will chair the Compensation and Stock Option Committee.
📋 Key Facts
- Steven A. Rosgen tendered his resignation on March 12, 2026, effective April 1, 2026.
- Kathy V. Turner was elected to the Board effective April 1, 2026.
- Ms. Turner will serve on the Audit Committee and as Chair of the Compensation and Stock Option Committee.
- Ms. Turner brings over 30 years of experience, including roles as Chief Marketing Officer at IDEXX Laboratories and leadership positions at Abbott Laboratories.
- The transition was previously signaled in an 8-K filed on February 9, 2026.
ImmuCell Corporation announced its unaudited financial results for the fourth quarter and full fiscal year ended December 31, 2025. The disclosure was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing was made on March 4, 2026, reporting on the period ended December 31, 2025.
- The report includes both quarterly and full-year unaudited financial results.
- The information is furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- Timothy C. Fiori, CFO, signed the report.
ImmuCell Corporation announced that two directors, Steven A. Rosgen and Bryan K. Gathagan, will not seek re-election at the upcoming 2026 Annual Meeting of Shareholders due to time constraints.
🚩 Red Flags
- Loss of institutional knowledge via two simultaneous director departures (though non-adversarial).
📋 Key Facts
- Steven A. Rosgen has given notice he will not run for re-election at the 2026 Annual Meeting.
- Bryan K. Gathagan has given notice he will not run for re-election at the 2026 Annual Meeting.
- Both directors cited time constraints from full-time leadership roles as the reason for their departure.
- The departures are planned and coincide with an ongoing evaluation of Board composition by the Nominating Committee.
ImmuCell Corporation entered into new employment agreements for its CFO and SVP of Sales and Marketing, alongside a performance-based stock option grant for the CEO. The filings detail updated compensation structures including base salaries and potential cash bonuses tied to financial targets.
🚩 Red Flags
- The CEO's performance-based option is tied to a very high threshold (300% increase in net operating income), which may be difficult to achieve and could indicate aggressive growth expectations.
📋 Key Facts
- Effective Jan 27, 2026, Timothy C. Fiori (CFO) entered a new agreement with an annual base salary of $315,000.
- Effective Jan 27, 2026, Bobbi Jo Brockmann (SVP Sales & Marketing) entered a new agreement with an annual base salary of $300,000.
- Both Fiori and Brockmann are eligible for cash bonuses of 50% to 60% of their base salary based on financial/strategic targets.
- Fiori granted stock options for up to 120,000 shares at $6.26 per share; Brockmann granted options for up to 100,000 shares at $6.26 per share.
- CEO Olivier te Boekhorst received a performance-based stock option for 110,000 shares at $6.26/share, contingent on net operating income exceeding 300% of FY2025 audited levels for four consecutive quarters.
ImmuCell Corporation announced approximately $3.6 million in non-cash impairment write-downs for the period ending December 31, 2025. The primary driver is a strategic shift away from its Re-Tain® product line following an FDA Incomplete Letter regarding its contract manufacturer.
🚩 Red Flags
- Strategic pivot necessitated by regulatory/manufacturing failure (FDA Incomplete Letter).
- Significant impairment of a major asset line (Re-Tain®), representing a substantial portion of its book value.
- Inventory loss due to product being deemed unfit for processing.
📋 Key Facts
- Total estimated non-cash impairment write-down: ~$3.6 million.
- Re-Tain® assets (net book value $15.5M as of Sept 30, 2025) facing a $2.9 million write-down due to paused investment and FDA issues.
- FDA issued an Incomplete Letter to the Company's contract manufacturer regarding inspectional deficiencies.
- Additional $0.7 million in impairments related to equipment ($0.1M) and colostrum inventory ($0.6M) unfit for First Defense® production.
ImmuCell Corporation is pivoting its business strategy following an FDA 'Incomplete Letter' regarding its Re-Tain® New Animal Drug Application. This strategic shift involves pausing investment in Re-Tain® and repurposing assets to focus on the First Defense® franchise, resulting in a $2.3 million non-cash impairment charge.
🚩 Red Flags
- Regulatory setback: Receipt of an FDA Incomplete Letter for a primary product candidate (Re-Tain®).
- Significant non-cash impairment charge ($2.3 million) related to the abandonment/repurposing of production assets.
- Strategic pivot often indicates failure of previous core development milestones.
📋 Key Facts
- FDA issued an 'Incomplete Letter' for the Re-Tain® New Animal Drug Application (NADA) on December 23, 2025.
- Company is pausing further investment in the Re-Tain® product line.
- ImmuCell will increase investment in its First Defense® franchise.
- A non-cash impairment write-down of approximately $2.3 million for property, plant, and equipment (primarily equipment) is expected in Q4 2025.
- Affected assets are being repurposed from Re-Tain® production to First Defense® manufacturing.
ImmuCell Corporation has filed an 8-K to announce its unaudited financial results for the quarter ended September 30, 2025. The filing serves as a formal announcement of the earnings release issued on November 13, 2025.
📋 Key Facts
- Company announced unaudited financial results for the quarter ending September 30, 2025.
- The announcement was made via press release dated November 13, 2025.
- The filing includes Exhibit 99.1 containing the full text of the press release.
ImmuCell Corporation announced a leadership transition where Michael F. Brigham stepped down as President, CEO, Secretary, and Treasurer to become Special Advisor, effective November 1, 2025. Olivier te Boekhorst has been appointed as the new President and CEO.
🚩 Red Flags
- Sudden departure of a founder/long-term executive from primary leadership roles (CEO, President, Secretary, Treasurer) into an advisory role can sometimes signal internal friction or transition stress.
📋 Key Facts
- Olivier te Boekhorst appointed as President and CEO effective November 1, 2025.
- Michael F. Brigham stepped down from all executive roles (President, CEO, Secretary, Treasurer) to become Special Advisor to the CEO.
- The Board of Directors expanded from seven to nine members.
- Olivier te Boekhorst and Timothy C. Fiori elected to the Board of Directors.
- Timothy C. Fiori appointed as Secretary and Treasurer.
ImmuCell Corporation issued a press release announcing preliminary, unaudited product sales for the quarter ended September 30, 2025. This is a routine earnings-related update regarding operational performance.
📋 Key Facts
- Announcement date: October 7, 2025
- Reporting period: Quarter ended September 30, 2025
- Content: Preliminary, unaudited product sales results
- Signatories: Michael F. Brigham (CEO/PFO) and Timothy C. Fiori (CFO)
ImmuCell Corporation announced a leadership transition where Olivier te Boekhorst will succeed Michael F. Brigham as President and CEO, effective November 1, 2025. The transition includes a two-month advisory period for the outgoing CEO to ensure continuity.
🚩 Red Flags
- Significant equity inducement awards granted prior to official commencement of employment (September 16 vs November 1).
📋 Key Facts
- Olivier te Boekhorst appointed as President and CEO, effective November 1, 2025.
- Mr. te Boekhorst's background includes leadership roles at IDEXX Laboratories and Archimed; previously a consultant at Boston Consulting Group.
- Compensation for new CEO: $450,000 base salary, up to $400,000 annual cash bonus, and a $100,000 signing bonus.
- Inducement equity awards include 76,673 nonqualified stock options at an exercise price of $5.90 per share (granted Sept 16, 2025) and up to 85,000 additional shares in a second installment.
- Outgoing CEO Michael F. Brigham will serve as Special Advisor to the CEO for at least two months starting November 1, 2025.
- The Board of Directors plans to expand its size following the appointment.
ImmuCell Corporation has entered into an amendment to its existing $1 million line of credit with Maine Community Bank. The amendment extends the maturity date of the facility through September 11, 2026.
🚩 Red Flags
- Small total facility size ($1M) relative to typical micro-cap operational needs may indicate limited access to traditional capital markets.
📋 Key Facts
- Entered into an Allonge to and Amendment of Line of Credit on August 20, 2025.
- The existing $1 million line of credit with Maine Community Bank (MCB) is extended through September 11, 2026.
- Interest rate on borrowings is variable at the National Prime Rate per annum.
ImmuCell Corporation has filed an 8-K to announce its unaudited financial results for the fiscal quarter ended June 30, 2025. The filing serves as a formal announcement of the earnings press release issued on August 14, 2025.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025
- Filing date: August 14, 2025
- The filing includes unaudited financial results via a press release (Exhibit 99.1)
- Signed by Michael F. Brigham (CEO/PFO) and Timothy C. Fiori (CFO)
ImmuCell Corporation entered into a new $2.33 million loan agreement with Maine Community Bank to refinance existing debt obligations from MCB and FAME.
🚩 Red Flags
- Debt is secured by 'substantially all of the Company’s assets', increasing collateral risk for equity holders.
- Refinancing existing debt suggests a need to manage cash flow or interest expense obligations.
📋 Key Facts
- Entered into a Loan Agreement and Promissory Note on August 7, 2025.
- New principal amount: $2,327,119.
- Interest rate: 6.5% fixed per annum.
- Proceeds used to pay off an MCB loan ($1,525,852 at 7%) and a FAME loan ($768,209 at 8%).
- The new loan is secured by substantially all of the Company's assets.
ImmuCell Corporation issued a press release regarding its preliminary, unaudited product sales for the quarter ended June 30, 2025. The filing serves as a formal announcement of these operational results.
📋 Key Facts
- Announcement date: July 9, 2025
- Reporting period: Quarter ended June 30, 2025
- Content: Preliminary, unaudited product sales figures
- The information is provided under Item 2.02 and is considered 'furnished' rather than 'filed', limiting liability under Section 18.
ImmuCell Corporation issued an 8-K to announce the commencement of a CEO succession planning process. The filing refers to a press release detailing the transition strategy.
🚩 Red Flags
- Succession planning often precedes an official departure of the current CEO, which can introduce management uncertainty.
📋 Key Facts
- The company announced its 'CEO Succession Planning Process' on June 25, 2025.
- The announcement was made via a press release (Exhibit 99.1).
- Current leadership includes Michael F. Brigham (President and CEO) and Timothy C. Fiori (CFO).
ImmuCell Corporation held its 2025 Annual Meeting of Stockholders on June 12, 2025. While the election of directors and ratification of auditors were approved, shareholders rejected both a non-binding advisory resolution on executive compensation and a proposal to increase shares reserved for the 2017 Stock Option and Incentive Plan.
🚩 Red Flags
- Shareholder rejection of executive compensation advisory resolution (indicates potential misalignment between management and shareholders).
- Failure to approve the expansion of the 2017 Stock Option and Incentive Plan, which may limit the company's ability to issue equity-based compensation for future talent acquisition/retention.
📋 Key Facts
- The 2025 Annual Meeting was held via remote communication on June 12, 2025.
- All seven director nominees were elected to one-year terms with significant majority support (approx. 3.3M votes each).
- Shareholders voted against the non-binding advisory resolution on executive compensation (42.66% in favor).
- Shareholders rejected the amendment to increase shares reserved for the 2017 Stock Option and Incentive Plan from 650,000 to 900,000 shares (41.10% in favor).
- Wipfli LLP was ratified as the Independent Registered Public Accounting Firm for the year ending December 31, 2025.
- Quorum was established with 7,048,097 shares representing >78% of total outstanding eligible votes.
ImmuCell Corporation has filed an 8-K to announce its unaudited financial results for the quarter ended March 31, 2025. The filing serves as a formal announcement of the earnings release issued on May 14, 2025.
📋 Key Facts
- Report date: May 14, 2025
- Reporting period: Quarter ended March 31, 2025
- The results are unaudited financial results as per Item 2.02
- CEO/PFO is Michael F. Brigham
ImmuCell Corporation issued a press release regarding its preliminary, unaudited product sales for the quarter ended March 31, 2025. This is a routine disclosure of operational performance metrics.
📋 Key Facts
- Report date: April 8, 2025
- Subject matter: Preliminary, unaudited product sales for Q1 2025 (ended March 31, 2025)
- The information is furnished but not 'filed' under Section 18 of the Exchange Act.
ImmuCell Corporation has appointed Timothy C. Fiori as the new Chief Financial Officer, effective April 7, 2025. Mr. Fiori joins from Idexx Laboratories, bringing significant industry experience.
📋 Key Facts
- Timothy C. Fiori appointed as CFO effective April 7, 2025.
- Fiori previously served at Idexx Laboratories (Nasdaq: IDXX) for 24 years, most recently as Senior Director Finance, Commercial Operations.
- Annual base salary set at $250,000.
- Compensation includes participation in the 2017 Stock Option and Incentive Plan and a separate Incentive Compensation Agreement providing cash bonuses based on specific objectives.
ImmuCell Corporation announced its unaudited financial results for the quarter and fiscal year ended December 31, 2024. The filing serves as a formal announcement of the release of these earnings figures via press release.
📋 Key Facts
- Report date: February 25, 2025
- Reporting period: Quarter and Year ended December 31, 2024
- Financial results provided are unaudited
- The filing includes a press release as Exhibit 99.1
ImmuCell Corporation announced on January 16, 2025, that it has reached a settlement regarding an insurance claim. The claim was related to production contamination events previously experienced by the company.
🚩 Red Flags
- Historical mention of 'production contamination events' suggests past operational/quality control issues.
📋 Key Facts
- Settlement of an insurance claim has been finalized as of January 16, 2025.
- The underlying cause for the claim was 'certain production contamination events'.
- The filing is categorized under Item 8.01 (Other Events) and is furnished but not filed.
ImmuCell Corporation issued a press release announcing preliminary, unaudited product sales for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of operational results via Item 2.02.
📋 Key Facts
- Announcement date: January 9, 2025
- Subject matter: Preliminary, unaudited product sales for the year ended December 31, 2024
- Reporting period: Full fiscal year 2024
- The information is furnished under Item 2.02 and not 'filed' for purposes of Section 18 liability.
ImmuCell Corporation announced that Elizabeth L. Williams, Vice President of Manufacturing Operations, will transition to a part-time role effective December 6, 2024, ahead of her retirement on July 1, 2025.
🚩 Red Flags
- Succession risk: The departure of a long-tenured executive (since 2016) in a critical manufacturing role can disrupt operations if the transition is not managed effectively.
📋 Key Facts
- Elizabeth L. Williams has served as VP of Manufacturing Operations since April 2016.
- The parties entered into an Employment and Separation Agreement on December 6, 2024.
- Ms. Williams will work part-time through July 1, 2025, to facilitate a transition of duties.
- A one-time payment of $100,000 (less wages earned) is contingent upon her remaining employed and complying with the agreement through June 30, 2025.
ImmuCell Corporation entered into an Amending Agreement with Norbrook Laboratories Limited on November 29, 2024. The amendment modifies their existing development and supply agreement for the company's Re-Tain™ product and sets a termination date of March 31, 2026.
🚩 Red Flags
- Defined termination date for a key manufacturing/supply partner (March 31, 2026) creates a deadline for the company to secure new manufacturing or commercialize effectively before supply ceases.
📋 Key Facts
- Amending Agreement entered into with Norbrook Laboratories Limited on November 29, 2024.
- The agreement pertains to formulation, aseptic filling, and packaging services for Re-Tain™ (purified Nisin treatment).
- Norbrook will complete the manufacture of current in-process inventory.
- The Agreement is scheduled to terminate on March 31, 2026.
ImmuCell Corporation has filed an 8-K to announce its unaudited financial results for the quarterly period ended September 30, 2024. The filing serves as a formal notice that a press release containing these results was issued on November 13, 2024.
📋 Key Facts
- The company released unaudited financial results for the quarter ending September 30, 2024.
- The announcement was made via a press release dated November 13, 2024.
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
ImmuCell Corporation issued an 8-K to announce preliminary, unaudited product sales for the three-month and nine-month periods ending September 30, 2024. The filing serves as a formal announcement of operational performance results via a press release.
📋 Key Facts
- Report date: October 8, 2024
- Reporting period: Three-month and nine-month periods ended September 30, 2024
- Content: Preliminary, unaudited product sales results
- Exhibits: Press release attached as Exhibit 99.1
ImmuCell Corporation entered into a fifth amendment to its lease agreement with TVP, LLC regarding tenant improvements at its Portland, Maine facility. The amendment restructures a large upcoming rent payment due in January 2025 into smaller monthly payments and a deferred lump sum.
🚩 Red Flags
- Restructuring of significant upcoming debt/rent obligations suggests potential liquidity or cash flow management issues.
- The company is deferring a large lump sum to later in the year, which may indicate tight working capital.
📋 Key Facts
- Entered into Fifth Amendment of Lease on September 20, 2024, with TVP, LLC.
- Restructures a one-time rent payment of $368,743 originally due in January 2025.
- New terms: Monthly payments of $20,000 from January 2025 through June 2025.
- A final one-time payment of $248,743 is scheduled for July 2025.
ImmuCell Corporation announced its unaudited financial results for the quarterly period ended June 30, 2024. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Quarter ended June 30, 2024
- The results announced are unaudited
- CEO/PFO is Michael F. Brigham
ImmuCell Corporation issued a press release on July 9, 2024, announcing preliminary, unaudited product sales for the three-month and six-month periods ending June 30, 2024.
📋 Key Facts
- Announcement date: July 9, 2024
- Reporting period: Three-month and six-month periods ended June 30, 2024
- Nature of data: Preliminary, unaudited product sales figures
- The information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
ImmuCell Corporation entered into a Fourth Amendment of Lease with TVP, LLC to restructure payment terms for tenant improvements at its Portland, Maine facility. The amendment converts a large lump-sum payment due in July 2024 into smaller monthly installments and a deferred final payment.
🚩 Red Flags
- Liquidity management indicator: The company is restructuring a large upcoming cash outflow ($488k) into smaller installments to manage immediate cash flow needs.
- Potential liquidity strain: While the monthly payments are lower, the total amount due by January 2025 remains significant for a micro-cap entity.
📋 Key Facts
- Lease Amendment signed on June 11, 2024, with Landlord TVP, LLC.
- Revises terms for tenant improvement payments at 175 Industrial Way, Portland, Maine.
- Original obligation: A one-time rent payment of $488,743 due in July 2024.
- New structure: Monthly rent payments of $20,000 from July 2024 through December 2024.
- Final lump sum: A one-time payment of $368,743 scheduled for January 2025.
ImmuCell Corporation held its 2024 Annual Meeting of Stockholders on June 13, 2024. The meeting resulted in the election of seven directors and the ratification of Wipfli LLP as the independent auditor.
📋 Key Facts
- The 2024 Annual Meeting was held via remote communication (dial-in/webcast) on June 13, 2024.
- A quorum was present representing 6,071,108 shares, which is >78% of total outstanding eligible votes.
- All seven director nominees were elected to one-year terms.
- The non-binding advisory resolution on executive compensation was approved with 66% in favor of the voting shares.
- Wipfli LLP was ratified as the Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2024, with 99.5% approval.
ImmuCell Corporation issued an 8-K to announce a press release regarding regulatory status updates for its product development initiative, Re-Tain®.
📋 Key Facts
- The filing was made on June 6, 2024, reporting events from June 5, 2024.
- The company is providing an update on the regulatory status of its 'Re-Tain®' product development initiative.
- Information provided under Item 8.01 is furnished but not filed for purposes of Section 18 liability.
ImmuCell Corporation has filed an 8-K to announce its unaudited financial results for the quarterly period ended March 31, 2024.
📋 Key Facts
- The filing relates to the announcement of unaudited financial results for the quarter ended March 31, 2024.
- The report was filed on May 14, 2024.
- Financial results were released via a press release attached as Exhibit 99.1.
ImmuCell Corporation entered into an At-The-Market (ATM) offering agreement with Craig-Hallum Capital Group LLC to sell up to $11,000,000 of common stock. This follows a recent S-3 shelf registration becoming effective on April 9, 2024.
🚩 Red Flags
- Potential for significant shareholder dilution due to the $11M ATM offering capacity.
- The need to amend existing loan agreements specifically to permit equity issuance suggests previous restrictive covenants were in place.
📋 Key Facts
- Entered into an At The Market (ATM) Offering Agreement with Craig-Hallum Capital Group LLC on April 9, 2024.
- The agreement allows for the sale of up to $11,000,000 of common stock.
- Sales Agent compensation is set at 3.0% of gross proceeds.
- Shares will be issued under a Form S-3 shelf registration (File No. 333-278438) declared effective on April 9, 2024.
- The company amended its FAME Loan Agreement on April 8, 2024, to remove restrictions on issuing equity securities.
ImmuCell Corporation issued an 8-K to announce unaudited product sales results for the first quarter of 2024, ending March 31, 2024.
📋 Key Facts
- The filing reports on unaudited product sales for the three-month period ended March 31, 2024.
- Report date: April 9, 2024.
- Information is provided via a press release attached as Exhibit 99.1.
ImmuCell Corporation entered into an Amending Agreement with Norbrook Laboratories Limited on March 4, 2024. The amendment modifies their existing Development Services and Commercial Supply Agreement for the company's Re-Tain™ product and includes a termination clause.
🚩 Red Flags
- Automatic termination clause set for November 30, 2024, creates significant near-term operational and supply chain uncertainty for the Re-Tain™ product line.
- The company faces a critical deadline to secure new manufacturing/supply partners or renegotiate terms before year-end.
📋 Key Facts
- Amended agreement dated March 4, 2024, with Norbrook Laboratories Limited.
- The original agreement (dated Sept 5, 2019) covers formulation, aseptic filling, and packaging for Re-Tain™ at an FDA-licensed facility.
- The Amendment includes a provision for automatic termination of the Agreement on November 30, 2024.
ImmuCell Corporation has extended its $1 million line of credit with Gorham Savings Bank through September 11, 2025. Additionally, lenders have waived minimum debt service coverage ratio requirements for the period ending June 30, 2024.
🚩 Red Flags
- Waiver of debt service coverage ratio requirements indicates potential difficulty in meeting financial covenants.
- Small total credit facility ($1 million) relative to the need for waivers suggests tight liquidity management.
📋 Key Facts
- Entered into an Allonge to and Amendment of Line of Credit with Gorham Savings Bank (GSB) on February 22, 2024.
- The $1 million line of credit is now extended through September 11, 2025.
- Gorham Savings Bank waived the minimum debt service coverage ratio (DSC) requirement of 1.35 for the period ending June 30, 2024.
- Finance Authority of Maine (FAME) also waived the DSC requirement for the same period on February 26, 2024.
ImmuCell Corporation issued an 8-K to announce its unaudited financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: February 27, 2024
- Reporting period: Quarter and Year ended December 31, 2023
- The filing contains unaudited financial results via a press release (Exhibit 99.1)
- CEO/PFO Michael F. Brigham signed the report
ImmuCell Corporation issued a press release announcing its unaudited product sales for the fiscal year ended December 31, 2023. This is a routine disclosure of operational results under Item 2.02.
📋 Key Facts
- Report date: January 8, 2024
- Subject matter: Unaudited product sales for the year ended December 31, 2023
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.